Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.
Also called NCT03764241
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 280 participants
- Sponsor
- Registry
-
NCT03764241
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03764241. Randomized; no masking; primary purpose treatment. Start 2020-02-01 (actual); primary completion 2022-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
- Acronym
- EARLYmyo-LVT
- Condition
- ST Segment Elevation Myocardial Infarction
- Condition
- Left Ventricular Thrombus
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Vitamin K Antagonist
- Lead sponsor
- RenJi Hospital
- Collaborator
- Shanghai 6th People's Hospital
- Collaborator
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Collaborator
- Shanghai Minhang Central Hospital
- Collaborator
- Shanghai Songjiang Central Hospital
- Collaborator
- Shanghai Fengxian District Central Hospital
- Collaborator
- Zhoushan Hospital in Zhejiang Province
Record details
- Record id
cardio:ct-nct03764241- Content hash
227d5464449c6cab65af0d5a2f5e9c8ce428be92b3b7fe71a6ce5b8b9c29ec26